Journal article
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Abstract
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease.
METHODS: REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 …
Authors
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L
Journal
The Lancet, Vol. 394, No. 10193, pp. 131–138
Publisher
Elsevier
Publication Date
7 2019
DOI
10.1016/s0140-6736(19)31150-x
ISSN
0140-6736